Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OBIO Stock Forecast 2025-2026
$2.65
Current Price
$101.53M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OBIO Price Targets
+654.7%
To High Target of $20.00
+352.8%
To Median Target of $12.00
+352.8%
To Low Target of $12.00
OBIO Price Momentum
+3.5%
1 Week Change
-11.1%
1 Month Change
-43.7%
1 Year Change
-33.8%
Year-to-Date Change
-70.1%
From 52W High of $8.87
+11.8%
From 52W Low of $2.37
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Health Sciences 2 (OBIO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OBIO and similar high-potential opportunities.
Latest OBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, OBIO has a bullish consensus with a median price target of $12.00 (ranging from $12.00 to $20.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $2.65, the median forecast implies a 352.8% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Keay Nakae at Chardan Capital, projecting a 654.7% upside. Conversely, the most conservative target is provided by Matt Miksic at Barclays, suggesting a 352.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OBIO Analyst Ratings
7
Buy
0
Hold
0
Sell
OBIO Price Target Range
Low
$12.00
Average
$12.00
High
$20.00
Current: $2.65
Latest OBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 5, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $12.00 |
| Apr 22, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $20.00 |
| Apr 4, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $12.00 |
| Apr 1, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $20.00 |
| Mar 20, 2025 | BTIG | Marie Thibault | Buy | Initiates | $12.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Jan 2, 2025 | Barclays | Matt Miksic | Overweight | Initiates | $16.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Nov 13, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $20.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $14.00 |
| Jul 25, 2024 | B. Riley Securities | Kyle Bauser | Buy | Initiates | $15.00 |
| Jun 12, 2024 | Chardan Capital | Keay Nakae | Buy | Reiterates | $20.00 |
| Mar 28, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $20.00 |
| Jan 19, 2024 | Jefferies | Matthew Taylor | Buy | Initiates | $14.00 |
| Aug 11, 2023 | Chardan Capital | Keay Nakae | Buy | Reiterates | $20.00 |
| Aug 9, 2023 | Chardan Capital | Keay Nakae | Buy | Reiterates | $20.00 |
| May 15, 2023 | Chardan Capital | Keay Nakae | Buy | Reiterates | $20.00 |
| Feb 24, 2023 | Piper Sandler | Matt O'Brien | Overweight | Initiates | $15.00 |
| Feb 7, 2023 | Chardan Capital | Keay Nakae | Buy | Initiates | $20.00 |
Orchestra BioMed Holdings, Inc. (OBIO) Competitors
The following stocks are similar to Health Sciences 2 based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Orchestra BioMed Holdings, Inc. (OBIO) Financial Data
Orchestra BioMed Holdings, Inc. has a market capitalization of $101.53M with a P/E ratio of 0.0x. The company generates $2.64M in trailing twelve-month revenue with a 92.3% profit margin.
Revenue growth is -3.4% quarter-over-quarter, while maintaining an operating margin of -6,591.7% and return on equity of -120.8%.
Valuation Metrics
Market Cap
$101.53M
Enterprise Value
$59.67M
P/E Ratio
0.0x
PEG Ratio
-1.5x
Price/Sales
38.5x
Growth & Margins
Revenue Growth (YoY)
-3.4%
Gross Margin
+77.1%
Operating Margin
-6,591.7%
Net Margin
+92.3%
EPS Growth
-3.4%
Financial Health
Cash/Price Ratio
+65.8%
Current Ratio
4.3x
Debt/Equity
50.2x
ROE
-120.8%
ROA
-46.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Orchestra BioMed Holdings, Inc. (OBIO) Business Model
About Orchestra BioMed Holdings, Inc.
What They Do
Develops innovative biomedical therapies for healthcare.
Business Model
The company focuses on developing and commercializing advanced medical therapies, particularly in the cardiovascular sector. It generates revenue through partnerships with healthcare organizations, leveraging its proprietary bioelectronics and drug delivery technologies to address unmet medical needs.
Additional Information
Orchestra BioMed is committed to enhancing patient outcomes by integrating technology with clinical applications. Its collaborative approach with major healthcare partners accelerates the development and deployment of its solutions, positioning it as a significant player in biomedical research and healthcare innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
70
CEO
Mr. David P. Hochman
Country
United States
IPO Year
2020
Website
orchestrabiomed.comOrchestra BioMed Holdings, Inc. (OBIO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -1.95% and 1.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2025
By Zacks Equity Research
Tale of the Tape
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
May 05, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Orchestra BioMed Holdings, Inc. (OBIO) is anticipated to potentially exceed earnings expectations in its upcoming report, driven by favorable conditions.
Why It Matters
Orchestra BioMed Holdings may exceed earnings expectations, potentially boosting stock value and attracting investor interest, indicating strong performance ahead.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Orchestra BioMed Holdings (Nasdaq: OBIO) announced it has secured 10 new patents for its AVIM therapy pipeline and 17 patents for heart failure treatments, expanding its global IP estate.
Why It Matters
The expansion of Orchestra BioMed's patent portfolio enhances its competitive edge, potentially increasing its market value and attracting investment interest in its innovative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Orchestra BioMed's Virtue SAB, a unique non-coated drug-eluting balloon, has FDA approval to start the Virtue Trial in H2 2025, comparing it to a paclitaxel-coated balloon for coronary ISR.
Why It Matters
Orchestra BioMed's FDA approval for the Virtue Trial positions it uniquely in the market with a promising drug-eluting balloon. Successful results could enhance its competitive edge and attract investment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) will participate in several upcoming institutional investor conferences, focusing on its biomedical technologies and partnerships.
Why It Matters
Orchestra BioMed's participation in investor conferences signals potential growth and increased visibility, which may attract institutional investment and boost stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
19 days ago
Quick Summary
The FDA granted Breakthrough Device Designation to Orchestra BioMed's AVIM therapy for uncontrolled hypertension. A symposium will showcase its efficacy and ongoing studies.
Why It Matters
The FDA's Breakthrough Device Designation for AVIM therapy signals potential market advantages for Orchestra BioMed, enhancing investor confidence in future revenue growth and partnership opportunities with Medtronic.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Orchestra BioMed Holdings, Inc. announced FDA Breakthrough Device Designation for its atrioventricular interval modulation therapy, aimed at accelerating access to this technology.
Why It Matters
FDA’s Breakthrough Device Designation for Orchestra BioMed’s AVIM therapy signals potential faster market access and significant competitive advantage, likely boosting stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About OBIO Stock
What is Orchestra BioMed Holdings, Inc.'s (OBIO) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Orchestra BioMed Holdings, Inc. (OBIO) has a median price target of $12.00. The highest price target is $20.00 and the lowest is $12.00.
Is OBIO stock a good investment in 2025?
According to current analyst ratings, OBIO has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OBIO stock?
Wall Street analysts predict OBIO stock could reach $12.00 in the next 12 months. This represents a 352.8% increase from the current price of $2.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Orchestra BioMed Holdings, Inc.'s business model?
The company focuses on developing and commercializing advanced medical therapies, particularly in the cardiovascular sector. It generates revenue through partnerships with healthcare organizations, leveraging its proprietary bioelectronics and drug delivery technologies to address unmet medical needs.
What is the highest forecasted price for OBIO Orchestra BioMed Holdings, Inc.?
The highest price target for OBIO is $20.00 from Keay Nakae at Chardan Capital, which represents a 654.7% increase from the current price of $2.65.
What is the lowest forecasted price for OBIO Orchestra BioMed Holdings, Inc.?
The lowest price target for OBIO is $12.00 from Matt Miksic at Barclays, which represents a 352.8% increase from the current price of $2.65.
What is the overall OBIO consensus from analysts for Orchestra BioMed Holdings, Inc.?
The overall analyst consensus for OBIO is bullish. Out of 7 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are OBIO stock price projections?
Stock price projections, including those for Orchestra BioMed Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 10:34 AM UTC